CRISPR-Cas9 Knockout Screens Identify DNA Damage Response Pathways and BTK as Essential for Cisplatin Response in Diffuse Large B-Cell Lymphoma

The recurrence of diffuse large B-cell lymphoma (DLBCL) has been observed in 40% of cases. The standard of care for refractory/relapsed DLBCL (RR-DLBCL) is platinum-based treatment prior to autologous stem cell transplantation; however, the prognosis for RR-DLBCL patients remains poor. Thus, to iden...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancers 2024-07, Vol.16 (13), p.2437
Hauptverfasser:	Issa, Issa Ismail, Due, Hanne, Brøndum, Rasmus Froberg, Veeravakaran, Vidthdyan, Haraldsdóttir, Hulda, Sylvester, Cathrine, Brogaard, Asta, Dhanjal, Soniya, Schmierer, Bernhard, Dybkær, Karen
Format:	Artikel
Sprache:	eng
Schlagworte:	B-cell lymphoma B-cell receptor Cancer therapies Cell cycle Cell proliferation Cell therapy Chemotherapy Cisplatin Clinical trials CRISPR DNA damage Drug dosages Drug screening Flow cytometry Gene frequency Genes Genomes Genomics Immunosuppressive agents Lymphocytes B Lymphocytes T Lymphoma Medical prognosis Mutation Nucleotide excision repair Patients Platinum RNA polymerase Standard of care Stem cell transplantation Surveillance Transplants & implants
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!